Ascletis reports preclinical data for once-weekly oral obesity peptide pipeline
Lead candidate ASC360, a once-weekly oral amylin receptor agonist, has begun a Phase I study in the United States.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 19 20:10 ETSource: The Conway Daily Sun
The wire
- 01Ascletis says its once-weekly oral peptide pipeline covers four validated obesity targets and includes multiple fixed-dose combinations, with ASC360 the most advanced candidate.
- 02Oral peptide delivery and amylin analogs are the two areas most likely to reshape incretin competition beyond injectable semaglutide and tirzepatide.
- 03The data are preclinical and company-reported; Phase I results for ASC360 and any human efficacy or tolerability readouts are not yet available.
From the source
Read at conwaydailysun.comAscletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first - in-class fixed - dose combinations.
